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OBJECTIVES In a multicenter, randomized trial, systematic stenting using the Wiktor stent was compared
to conventional balloon angioplasty with provisional stenting for the treatment of acute
myocardial infarction (AMI).
BACKGROUND Primary angioplasty in AMI is limited by in-hospital recurrent ischemia and a high restenosis rate.
METHODS A total of 211 patients with AMI ,12 h from symptom onset, with an occluded native
coronary artery, were randomly assigned to systematic stenting (n 5 101) or balloon
angioplasty (n 5 110). The primary end point was the binary six-month restenosis rate
determined by core laboratory quantitative angiographic analysis.
RESULTS Angiographic success (Thrombolysis in Myocardial Infarction [TIMI] flow grade 3 and
residual diameter stenosis ,50%) was achieved in 86% of the patients in the stent group and
in 82.7% of those in the balloon angioplasty group (p 5 0.5). Compared with the 3%
cross-over in the stent group, cross-over to stenting was required in 36.4% of patients in the
balloon angioplasty group (p 5 0.0001). Six-month binary restenosis ($50% residual
stenosis) rates were 25.3% in the stent group and 39.6% in the balloon angioplasty group (p 5
0.04). At six months, the event-free survival rates were 81.2% in the stent group and 72.7%
in the balloon angioplasty group (p 5 0.14), and the repeat revascularization rates were 16.8%
and 26.4%, respectively (p 5 0.1). At one year, the event-free survival rates were 80.2% in the
stent group and 71.8% in the balloon angioplasty group (p 5 0.16), and the repeat
revascularization rates were 17.8% and 28.2%, respectively (p 5 0.1).
CONCLUSIONS In the setting of primary angioplasty for AMI, as compared with a strategy of conventional
balloon angioplasty, systematic stenting using the Wiktor stent results in lower rates of
angiographic restenosis. (J Am Coll Cardiol 2000;35:1729–36) © 2000 by the American
College of Cardiology
Primary coronary angioplasty for acute myocardial infarc-
tion (AMI) has been demonstrated to be a valuable method
of reperfusion, resulting in lower rates of mortality, recur-
rent myocardial infarction and stroke, as compared with
thrombolytic therapy (1–4). However, early recurrent isch-
emia still occurs in up to 15% of patients after an initially
successful procedure (4,5), and late restenosis (40% to 50%)
requiring repeat revascularization in the first six months
remains disappointingly high (6–8). Compared with bal-
loon angioplasty, elective coronary stenting has been shown
to reduce both restenosis and the need for target lesion
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revascularization during follow-up, resulting in an improved
late clinical outcome (9,10). Coronary stenting is no longer
considered as a contraindication in thrombus-containing
lesions (11,12) and may potentially overcome the limitations
of balloon angioplasty in the setting of AMI (13–16). We
report the results of the second STENTing In acute
Myocardial infarction (STENTIM-2) study, a multicenter,
randomized clinical trial comparing systematic coronary
stenting using the Wiktor (Medtronic) stent to conven-
tional balloon angioplasty with provisional stenting for the
treatment of AMI.
METHODS
STENTIM-2 is a multicenter, randomized trial comparing
systematic coronary stenting using the Wiktor stent to
conventional balloon angioplasty with provisional stenting
for the treatment of AMI. The study was designed and
powered to compare the rates of binary angiographic resten-
osis at systematic six-month angiographic follow-up.
The primary end point was binary angiographic resteno-
sis, defined as $50% residual stenosis on the follow-up
angiogram. Secondary end points included procedural suc-
cess, defined as residual stenosis ,50%, associated with
Thrombolysis in Myocardial Infarction (TIMI) flow grade 3
(17,18) and a composite end point combining either: 1)
death; 2) recurrent myocardial infarction, defined as recur-
rent symptoms lasting .30 min despite nitrate therapy with
new electrocardiographic (ECG) changes and either recur-
rent elevation of cardiac enzymes or emergency angio-
graphic confirmation of an occluded culprit vessel; or 3)
repeat revascularization of the target lesion, which included
either repeat angioplasty or bypass surgery of the target
vessel for restenosis with objective myocardial ischemia.
This composite end point was evaluated at 6- and 12-month
follow-up.
Secondary end points also included 1) recurrent ischemia,
defined as recurrent symptoms consistent with angina and
ECG changes sensitive to nitroglycerin and lasting
,30 min, with no recurrent elevation of cardiac enzymes;
and 2) reocclusion of the infarct-related artery, defined as
TIMI flow grade 0 or 1 with .50% residual diameter
stenosis on the follow-up angiogram of a previously patent
vessel.
Additional end points included cerebrovascular accidents,
access site bleeding, need for vascular repair or transfusion.
Revascularization of other lesions was not considered an end
point.
Patient selection. Patients .18 years old with prolonged
nitrate-resistant chest pain seen within 12 h of onset and ST
segment elevation were selected. Exclusion criteria included
participation in another study in the last month; thrombo-
lytic therapy; cardiogenic shock; history of coronary artery
bypass graft surgery; percutaneous transluminal coronary
angioplasty (PTCA) within the previous six months; con-
traindications to heparin, aspirin or ticlopidine, such as
allergy, thrombocytopenia or hemorrhagic diasthesis; severe
renal or liver failure; and weight ,40 or .100 kg. All
patients had ECG and enzyme confirmation of an AMI.
Emergency management and catheterization. Patients
received a 500-mg intravenous bolus of aspirin and at least
5,000 IU of intravenous heparin (additional boluses were
given as appropriate, according to the duration of the
procedure). Coronary and left ventricular (LV) angiography
was performed with the femoral approach using standard
techniques. Angiographic inclusion criteria included 1)
vessel diameter ,3.00 mm by local on-line quantitative
coronary analysis after maximal dilation induced by intra-
coronary nitroglycerin; 2) TIMI flow grade ,3; and 3)
culprit lesion diameter stenosis .70%. Bifurcation lesions
involving a major side branch, left main coronary artery
disease (stenosis .50%) and massively calcified lesions were
excluded. Patients were also excluded if the infarct-related
artery could not be identified or if they presented with severe
multiple-vessel disease requiring emergency bypass surgery.
After coronary angiography and before crossing the lesion
with a guide wire, the patients were randomly assigned by
computer to either conventional balloon angioplasty or stent
placement. The randomization sequence was designed to
ensure balanced randomization at each center. Recruitment
was limited to 25 patients per center.
Procedure. Angioplasty was performed using standard
techniques. The 6F guiding catheters were recommended.
Operators were instructed to attempt to achieve a residual
stenosis ,30%. Stenting was performed using the Wiktor
GX stent (Medtronic), which is a 16-mm-long coil stent.
Expansion is obtained by inflating the balloon catheter at
12 atm (19–21). Additional stents were placed according to
operator judgment to treat residual dissections. In the
balloon angioplasty group, cross-over to stent placement
was allowed for occlusive (bail-out) or nonocclusive exten-
sive (type C or more) dissections that could not be success-
fully treated by repeated prolonged balloon inflations (22), a
suboptimal result with residual stenosis of .50% or persis-
tent slow flow (TIMI flow grade ,3) (23).
The femoral sheath was removed, and hemostasis was
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ECG 5 electrocardiogram or
electrocardiographic
LV 5 left ventricle or ventricular
PTCA 5 percutaneous transluminal coronary
angioplasty
STENTIM-2 5 second STENTing In acute
Myocardial infarction study
TIMI 5 Thrombolysis In Myocardial Infarction
trial
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obtained by manual compression as soon as the activated
partial thromboplastin time was ,60 s. All patients then
received 100 international U of activity of low molecular
weight heparin subcutaneously twice daily for at least 48 h,
as well as 160 to 300 mg/day of aspirin (24). In addition,
ticlopidine (500 mg/day) was prescribed for one month to
all patients with stents. Angiotensin-converting enzyme
inhibitors and beta-blockers were administered according to
established guidelines.
Clinical and angiographic follow-up. Clinical follow-up
was obtained at six months and one year. Six-month repeat
coronary angiography was performed after a routine stress
test. Angiography performed before four months was al-
lowed on the basis of clinical indications. If restenosis was
not found, a new angiogram was required after four months.
All angiograms were sent to a core laboratory (Cardialysis,
Rotterdam, the Netherlands) for analysis using the Cardio-
vascular Angiography Analysis System and previously de-
scribed methods (25). The TIMI frame count was per-
formed on all angiograms (23).
Clinical and angiographic data were forwarded to the
Data Coordinating Center at the University of Tours,
France for statistical analysis. All adverse events were
analyzed by the members of the Critical Events Committee.
Analysis was done on an intention-to-treat basis.
Participating centers. Study centers and investigators were
selected on the basis of their experience with primary
angioplasty for AMI. A yearly case load of .150 per center
and .50 per investigator was required.
The study protocol was approved by the Institutional
Review Board of the Tours Hospital according to French
law, and written consent was obtained from all patients. The
study was conducted according to the Declaration of Hel-
sinki.
Statistical analysis. Sample size estimates (n 5 180) were
based on an assumed rate of restenosis of 50% (including a
10% occlusion rate) in the angioplasty group and a 50%
relative reduction in the stent group (two-sided test with an
alpha error of 0.025 and a power of 0.95). To compensate
for unsuccessful interventions and losses to follow-up, the
sample was enlarged by 10% (n 5 200). Results are
expressed as the mean value 6 SD for continuous variables.
The two-tailed t test was used to assess differences between
the treatment groups. Categoric data are presented as rates
and were compared using the chi-square test or the Fisher
exact test. Freedom from clinical end points was analyzed
using Kaplan-Meier survival curves. Differences between
the treatment groups were compared using the log-rank
test.
RESULTS
Between September 1997 and September 1998, 216 pa-
tients were randomly assigned to either balloon angioplasty
(n 5 112) or systematic stent implantation (n 5 104). Of
these 216 patients, five successfully treated patients were
excluded by the Critical Events Committee because of
major protocol violations. The final study group comprised
211 patients, with 101 and 110 patients in the stent and
balloon angioplasty groups, respectively (Fig. 1). Baseline
clinical (Table 1) and angiographic characteristics (Table 2)
were similar between the groups.
Hospital outcome. Angiographic success (TIMI flow
grade 3 and residual diameter stenosis ,50%) was achieved
in 86% and 82.7% of patients in the stent and balloon
angioplasty groups, respectively (p 5 0.5). Of the 101
Figure 1. Trial flow chart. pts 5 patients.
Table 1. Baseline Clinical Characteristics of the 211 Study
Patients (Intention-to-treat Analysis)
Stent
Group
(n 5 101)
Balloon
Angioplasty
Group
(n 5 110)
Age (yrs) 57.2 6 12.2 57.7 6 12.8
Male gender 85.1% 79.1%
Treated hypertension 25.7% 35.5%
Hypercholesterolemia .6.5
mmol/liter
42.6% 42.7%
Treated diabetes mellitus 13.9% 13.6%
Current smokers 55.5% 60.0%
Family history of CAD 34.7% 31.8%
History of angina 25.7% 25.5%
Previous myocardial infarction 5.0% 4.6%
Infarct location
Anterior 38.6% 33.6%
Inferior 54.5% 59.1%
Other 6.9% 7.3%
Chest pain, admission delay
(min)
213 6 128 239 6 127
Admission, reperfusion delay
(min)
67 6 54 66 6 58
Data are presented as the mean value 6 SD or percentage of patients.
CAD 5 coronary artery disease.
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patients assigned to stenting, three did not receive a stent—
one because of failure to cross the lesion and two because of
stent delivery failure. Those three patients were treated with
balloon angioplasty only. Of the 110 patients assigned to
balloon angioplasty, 40 ultimately required a stent. Cross-
over to stenting was thus seen in 36.4% of the balloon
angioplasty group, whereas cross-over to balloon angioplasty
was seen in 3% of the stent group (p , 0.001). Indications
for cross-over to stenting included bail-out in 17.5%,
nonocclusive extensive dissections in 15%, a suboptimal
result in 57.5% or persistent slow flow (TIMI flow grade 1
or 2) in 10% of patients. No stent delivery failure was
observed in this group. Procedural results are provided in
Table 3. The patients’ mean hospital stay was 10.0 6 5.5
days in the balloon angioplasty group and 10.4 6 8.9 days
in the stent group (p 5 0.71). In-hospital clinical events are
shown in Table 4; there were no differences between the
groups. One death occurred in the stent group due to free
wall rupture. Freedom from in-hospital major adverse car-
diac events was similar in both groups (95% in the stent
group vs. 94.5% in the balloon angioplasty group, p 5 0.87).
Angiographic results (Table 5). There was no difference
in the baseline culprit lesion angiographic characteristics.
The minimal lumen diameter after the procedure was
greater in the stent group than in the balloon angioplasty
group (2.38 6 0.39 vs. 2.11 6 0.49 mm, p , 0.001),
resulting in a larger early gain (2.28 6 0.48 vs. 1.99 6
0.53 mm, p , 0.001). Six-month angiographic follow-up
was obtained in 90% of eligible patients. The binary
restenosis rate was 25.3% in the stent group and 39.6% in
the balloon angioplasty group (p 5 0.04); this included
7.2% and 6.3% reocclusion rates in each group, respectively
(p 5 0.79). Cumulative distributions of minimal lumen
diameter and percent stenosis are illustrated in Figure 2.
Clinical follow-up. Clinical follow-up was available for all
patients (Table 4). At six months, the event-free survival
rates were 81.2% in the stent group and 72.7% in the
balloon angioplasty group (p 5 0.14) (Fig. 3), and the
repeat revascularization rates were 16.8% and 26.4%, re-
spectively (p 5 0.1) (Fig. 4). There was a nonsignificant
trend toward fewer repeat angioplasties in the stent group
versus the balloon angioplasty group (15.8% vs. 26.4%, p 5
0.06). These trends were sustained at one-year follow-up;
the event-free survival rates were 80.2% and 71.8% (p 5
0.16) and the repeat revascularization rates were 17.8% and
28.2% in the stent group and balloon angioplasty group,
respectively (p 5 0.1).
DISCUSSION
This randomized, multicenter trial shows that systematic
coronary stenting during primary angioplasty for AMI
significantly reduces the rates of six-month angiographic
binary restenosis. This difference was associated with fewer
clinical events and the need for target vessel revasculariza-
tion at six-month and one-year follow-up.
Use of ticlopidine and aspirin. Systematic stenting in the
setting of primary angioplasty was feasible and safe (13–15),
as demonstrated by the high success rate for stent deploy-
Table 2. Baseline Angiographic Characteristics
Stent Group
(n 5 101)
Balloon Angioplasty
Group (n 5 110)
No. of diseased vessels
1 68.3 60.9
2 21.8 30.0
3 9.9 9.1
LVEF (mean 6 SD) 54.1 6 12.8% 54.0 6 13.6%
Target vessel
LAD 38.6% 33.6%
RCA 45.6% 50.9%
LCx 15.8% 15.5%
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; LV 5 left ventricle; RCA 5 right coronary artery.
Table 3. Procedural Events
Stent Group
(n 5 101)
Balloon
Angioplasty
Group
(n 5 110)
p
Value
Heparin (IU, mean 6
SD)
First bolus 5,913 6 2,757 5,602 6 1,706 0.47
Periprocedural bolus 6,756 6 2,665 7,880 6 3,297 0.09
Abciximab (%) 3.0 2.7 0.92
Clinical events (%)
Death 0.0 0.0 1.0
Cerebrovascular
accident
0.0 0.0 1.0
Pulmonary edema 1.0 0.9 0.95
Allergy to contrast
agent
2.0 0.0 0.14
Access site
hemorrhage
0.0 0.0 1.0
Intraaortic balloon
inserted
3.0 3.6 0.79
Need for defibrillation 2.0 3.6 0.47
Need for prolonged
CPR
2.0 0.9 0.51
Cross-over (%) 3.0 36.4 0.0001
Patients with .1 stent
(%)
10.9 10.0 0.91
Indication for stenting
(%)
Systematic 100.0 — —
Bail-out — 17.5 —
Extensive dissection — 15.0 —
Suboptimal result — 57.5 —
TIMI flow grade ,3 — 10.0 —
CPR 5 cardiopulmonary resuscitation; TIMI 5 Thombolysis in Myocardial Infarc-
tion trial.
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ment (97%) and the low in-hospital mortality and morbidity
rates. This may be partially ascribed to the adjunctive
prescription of ticlopidine and aspirin, which has been
shown to reduce major events after elective coronary stent-
ing (24,26–29), and to the selection of experienced centers
and operators.
Clinical implications. In contrast to other trials of stenting
in primary angioplasty (30–32), in STENTIM-2 random-
ization was performed before attempted recanalization,
avoiding a bias toward selection of “ideal” lesions for
stenting. Our results are therefore relevant to daily clinical
practice. Despite these broad angiographic inclusion crite-
ria, the in-hospital rates of occlusion and the need for repeat
revascularization appear to be low in both groups, in
comparison to previously reported reocclusion rates up to
15% after balloon angioplasty for AMI (4,5), and are
comparable to those of nonrandomized trials of stenting for
AMI (16). The cross-over rate to provisional stenting
(36.4%) was higher than previously reported (30–32) and
probably reflects the current momentum of clinical practice
toward wider indications for stenting after incomplete or
unsatisfactory balloon angioplasty results (33). This may in
Table 4. In-Hospital Clinical Events and Outcomes
Stent
Group
(n 5 101)
Balloon
Angioplasty
Group
(n 5 110)
p
Value
Angiographic success (%)
TIMI flow grade 3 with
residual diameter
stenosis ,50%
86.0 82.7 0.50
TIMI flow grade 2 or 3
with residual
diameter stenosis
,50%
96 97.2 0.97
Hospital outcome at
discharge (%)
Death 1.0 0.0 0.48
Coronary ischemic
events
5.0 5.4 0.87
Recurrent ischemia 1.0 1.8 0.32
Reinfarction 4.0 3.6 1.0
Repeat angioplasty 5.0 5.4 0.87
Coronary artery bypass
graft surgery
0.0 0.0 1.0
Repeat revascularization 5.0 5.4 0.9
Event-free survival 95.0 94.5 0.87
Cumulative six-month
events (%)
Death 2.0 1.0 0.14
Coronary ischemic
events
12.9 18.8 0.29
Recurrent ischemia 8.9 13.3 0.28
Recurrent infarction 4.0 5.5 0.61
Repeat angioplasty 15.8 26.4 0.06
Coronary artery bypass
graft surgery
1.0 0.0 0.48
Repeat revascularization 16.8 26.4 0.1
Event-free survival 81.2 72.7 0.14
Cumulative 12-month
events (%)
Death 3.0 1.9 0.60
Coronary ischemic
events
12.9 20.0 0.16
Recurrent ischemia 8.9 14.5 0.19
Recurrent infarction 4.0 5.5 0.61
Repeat angioplasty 16.8 27.3 0.06
Coronary artery bypass
graft surgery
1.0 0.9 1.0
Repeat revascularization 17.8 28.2 0.1
Event-free survival 80.2 71.8 0.16
Bleeding and vascular
complications (%)
Access site bleeding 1.0 2.7 0.62
Need for vascular repair 0.0 0.9 1.0
Blood transfusion 2.0 1.8 1.0
Cerebrovascular accident 0.0 0.0 1.0
Discontinuation of
ticlopidine*
2.0 1.8 1.0
*Owing to intolerance.
TIMI 5 Thrombolysis in Myocardial Infarction.
Table 5. Angiographic Results
Stent Group
(n 5 101)
Balloon
Angioplasty
Group
(n 5 110) p Value
Before recanalization
MLD (mm) 0.10 6 0.28 0.12 6 0.31 0.6
Stenosis (% lumen
diameter)
96.21 6 10.43 96.22 6 10.44 0.74
After the procedure
Reference diameter
(mm)
2.96 6 0.43 2.95 6 0.46 0.89
MLD (mm) 2.38 6 0.39 2.11 6 0.49 ,0.001
Stenosis (% lumen
diameter)
19.44 6 8.08 28.45 6 10.79 ,0.001
At follow-up
Reference diameter
(mm)
2.88 6 0.54 2.82 6 0.52 0.48
MLD (mm) 1.66 6 0.73 1.50 6 0.62 0.10
Stenosis (% lumen
diameter)
42.45 6 21.7 46.79 6 19.69 0.16
Restenosis (%
patients)
25.3 39.6 0.0427
Including reocclusion
(% patients)
7.2 6.3 0.79
Ejection fraction (%) 56.3 6 10.5 56.5 6 10 0.92
Change in MLD
Early gain (mm)* 2.28 6 0.48 1.99 6 0.53 ,0.001
Late loss (mm)† 0.72 6 0.61 0.62 6 0.62 0.27
Net gain (mm)‡ 1.56 6 0.81 1.37 6 0.68 0.09
Data are presented as mean value 6 SD.
*Early gain is the postprocedural MLD minus the preprocedural MLD. †Late loss
is the postprocedural MLD minus the MLD at follow-up. ‡Net gain is the MLD at
follow-up minus the preprocedural MLD.
MLD 5 minimal lumen diameter.
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part explain the very low rate of in-hospital deaths and
complications.
Restenosis rate and event-free survival. This study was
designed and powered to evaluate the six-month angio-
graphic restenosis rate. Systematic stenting, compared with
balloon angioplasty, significantly reduced the restenosis rate.
This was associated, at six-month follow-up, with a 31.3%
relative reduction in coronary ischemic events and a 36.8%
relative reduction in the need for target vessel revasculariza-
tion in the stent group versus the balloon angioplasty group,
even though the protocol mandated that revascularization
be driven by noninvasive demonstration of ischemia. At
one-year follow-up, 80.2% of patients in the stent group
were event free. The study was not powered to detect
differences in clinical outcome or LV ejection fraction,
although there appears to be an interesting and consistent
improved event-free survival in the stent group at six- and
12-month follow-up. The similar event-free survival rates
between the groups during the hospital period and the
benefit in the stent group at both six and 12 months are
likely due to the reduction in restenosis rates, as suggested
by similar survival and revascularization rates at six months.
A larger sample may have yielded a greater clinical benefit of
systematic stenting.
Study limitations. The results of the study must be inter-
preted with caution given the sample size and the exclusion
of high risk patients, such as those with hemodynamic
compromise or failed thrombolysis. In addition, the proto-
col did not mandate adjunctive use of glycoprotein IIb/IIIa
inhibitors. Recent studies have suggested benefit in terms of
procedural and short-term results with abciximab during
primary PTCA (34–36), although this benefit was not
sustained at six months (35). Only a small fraction of the
patients enrolled in STENTIM-2 received abciximab (3%
in each group). Ongoing randomized trials are currently
evaluating the association between abciximab and primary
stenting for AMI. One of the limitations of the present
study was that only patients with stents received ticlopidine.
However, in this open trial, it was deemed unethical by the
Institutional Review Board to administer ticlopidine to the
patients not receiving stents, considering the potential for
severe, life-threatening hematologic complications, even
though these are rare. In addition, ticlopidine has not been
shown to have any impact on restenosis, which was the
primary end point of the trial. Despite these potential
limitations, STENTIM-2 involved randomization of un-
selected lesions and incorporated rigorous and blinded
adjudication of clinical and angiographic end points. Our
results are therefore clinically relevant.
Figure 2. Cumulative frequency distribution curves for the two
groups for minimal lumen diameter (MLD) at baseline, after the
procedure and at six-month follow-up. There was no difference at
baseline between the groups. After the procedure and at follow-up,
minimal lumen diameter was larger in the stent group (solid line)
than in the balloon angioplasty group (dashed line).
Figure 3. Kaplan-Meier survival curves for major adverse cardiac
events (MACE). At one year, 80.2% of the patients in the stent
group (solid line) were event free. Dashed line 5 balloon
angioplasty group.
Figure 4. Kaplan-Meier curves for second revascularization. There
were less patients in the stent group (solid line) than in the balloon
angioplasty group (dashed line) requiring a second revasculariza-
tion procedure.
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Conclusions. Systematic stenting during primary angio-
plasty for AMI is safe and feasible. It is associated with a
reduction in six-month restenosis and fewer clinical events
and target vessel revascularization at six months and one
year. This suggests that systematic stenting may be of
benefit for patients with AMI treated with primary PTCA.
APPENDIX
STENTIM-2
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CHU Tours (n 5 25): L. Maillard, B. Desveaux, L.
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Necker, Paris (n 5 17): F. Beygui, C. Le Feuvre, D. Catuli
and J.-P. Metzger; CHU Broussais, Paris (n 5 14): J.-L.
Guermonprez, S. Battaglia, K. Boughalem and P. Henry;
CHU Cochin, Paris (n 5 13): C. Spaulding, R. Cador, J.
Monsegu, A. Py, K. Benhamda, P. Richard and F. Belaou-
chi; Clinique St. Joseph, Colmar (n 5 13): J.-M. Boulenc,
A. Verdun, O. Katz, Y. Gottwalles, P.-L. Clermont and P.
Valentin; CHU Clermont-Ferrand (n 5 10): J. Lipiecki,
B. Citron and L. Sarfati; CHU Boucicaut, Paris (n 5 10):
A. Lafont, S. Rahal, P. Durand, K. Bougrini, F. Addad and
F. Labarthe; CHU Nantes (n 5 10): Ph. Brunel and D.
Crochet; CHU Caen (n 5 10): G. Grollier, E. Lecluse, R.
Sabatier, B. Valette, J. C. Potier and M. Hamon; CHU
Rouen (n 5 9): R. Koning, H. Eltchaninoff, C. Tron, B.
Baala and A. Cribier; CHU Bordeaux (n 5 4): P. Coste, S.
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